GSK Report Results of Otilimab in P-II OSCAR Study to Treat Hospitalized Patients with COVID-19

February 26, 2021 Auto Bot Clinical Trials, GSK, Report, results, Treatment 0

Shots:

  • The P-IIa POC OSCAR study involves assessing the efficacy and safety of otilimab (90mg, IV) + SOC vs PBO + SOC in 806 hospitalized adults with aged 18-79yrs. with severe COVID-19 related pulmonary disease
  • The study showed a 5.3% overall treatment difference in all age patients but did not reach statistically significant. The pre-planned efficacy analysis in the 70-plus cohort showed patients were alive and free of respiratory failure @28days (65.1% vs 45.9%)
  • The mortality analysis up to day60; 14.4% treatment difference favoring otilimab with rates of 40.4% for those who received SOC only vs 26% on otilimab plus SOC in patients aged≥17yrs.

Click here ­to­ read full press release/ article | Ref: GSK | Image: Online Market Reports

The post GSK Report Results of Otilimab in P-II OSCAR Study to Treat Hospitalized Patients with COVID-19 first appeared on PharmaShots.